Pathophysiological role of enhanced bone marrow adipogenesis in diabetic complications

References

• Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, et al.; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011; 378:31-40; PMID:21705069; http://dx.doi.org/10.1016/S0140-6736(11)60679-X
   PubMed Web of Science ®Google Scholar
• Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14(Suppl 5):S1-85; PMID:9450510; http://dx.doi.org/10.1002/(SICI)1096-9136(199712)14: 5±≤S7::AID-DIA522≥3.3.CO;2-I
   PubMedGoogle Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-53; PMID:15111519; http://dx.doi.org/10.2337/diacare.27.5.1047
   PubMed Web of Science ®Google Scholar
• An economic tsunami, the cost of diabetes in Canada. Toronto, Ontario: Canadian Diabetes Association, 2009.
   Google Scholar
• 2011 National Diabetes Fact Sheet, National Center for Chronic Disease Prevention and Health Promotion. American Diabetes Association 2011.
   Google Scholar
• Williams R, Van Gaal L, Lucioni C; CODE-2 Advisory Board. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002; 45:S13-7; PMID:12136406; http://dx.doi.org/10.1007/s00125-002-0859-9
   PubMed Web of Science ®Google Scholar
• Keats EC, Khan ZA. Vascular stem cells in diabetic complications: evidence for a role in the pathogenesis and the therapeutic promise. Cardiovasc Diabetol 2012; 11:37; PMID:22524626; http://dx.doi.org/10.1186/1475-2840-11-37
   PubMedGoogle Scholar
• Khan ZA, Chakrabarti S. Therapeutic targeting of endothelial dysfunction in chronic diabetic complications. Recent Pat Cardiovasc Drug Discov 2006; 1:167-75; PMID:18221084; http://dx.doi.org/10.2174/157489006777442531
   PubMedGoogle Scholar
• Khan ZA, Farhangkhoee H, Chakrabarti S. Towards newer molecular targets for chronic diabetic complications. Curr Vasc Pharmacol 2006; 4:45-57; PMID:16472176; http://dx.doi.org/10.2174/157016106775203081
   PubMedGoogle Scholar
• Howangyin KY, Silvestre JS. Diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction. Arterioscler Thromb Vasc Biol 2014; 34:1126-35; PMID:24675660; http://dx.doi.org/10.1161/ATVBAHA.114.303090
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Papageorgiou N, Androulakis E, Siasos G, Latsios G, Tentolouris K, Stefanadis C. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol 2013; 62:667-76; PMID:23948511; http://dx.doi.org/10.1016/j.jacc.2013.03.089
   PubMed Web of Science ®Google Scholar
• Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc Res 2008; 78:413-21; PMID:18349136; http://dx.doi.org/10.1093/cvr/cvn081
   PubMed Web of Science ®Google Scholar
• Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106:2781-6; PMID:12451003; http://dx.doi.org/10.1161/01.CIR.0000039526.42991.93
   PubMed Web of Science ®Google Scholar
• Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo M, de Kreutzenberg SV, Tiengo A, Agostini C, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45:1449-57; PMID:15862417; http://dx.doi.org/10.1016/j.jacc.2004.11.067
   PubMed Web of Science ®Google Scholar
• Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, Grego F, Vigili de Kreutzenberg S, Tiengo A, Agostini C, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006; 26:2140-6; PMID:16857948; http://dx.doi.org/10.1161/01.ATV.0000237750.44469.88
   PubMed Web of Science ®Google Scholar
• Botolin S, Faugere M-C, Malluche H, Orth M, Meyer R, McCabe LR. Increased bone adiposity and peroxisomal proliferator-activated receptor-γ2 expression in type I diabetic mice. Endocrinology 2005; 146:3622-31; PMID:15905321; http://dx.doi.org/10.1210/en.2004-1677
   PubMed Web of Science ®Google Scholar
• Botolin S, McCabe LR. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology 2007; 148:198-205; PMID:17053023; http://dx.doi.org/10.1210/en.2006-1006
   PubMed Web of Science ®Google Scholar
• Leidig-Bruckner G, Ziegler R. Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes 2001; 109(Suppl 2):S493-514; PMID:11460594; http://dx.doi.org/10.1055/s-2001-18605
   PubMed Web of Science ®Google Scholar
• Tuominen JT, Impivaara O, Puukka P, Rönnemaa T. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999; 22:1196-200; PMID:10388989; http://dx.doi.org/10.2337/diacare.22.7.1196
   PubMed Web of Science ®Google Scholar
• Wang A, Midura RJ, Vasanji A, Wang AJ, Hascall VC. Hyperglycemia diverts dividing osteoblastic precursor cells to an adipogenic pathway and induces synthesis of a hyaluronan matrix that is adhesive for monocytes. J Biol Chem 2014; 289:11410-20; PMID:24569987; http://dx.doi.org/10.1074/jbc.M113.541458
   PubMedGoogle Scholar
• Dhaliwal R, Cibula D, Ghosh C, Weinstock RS, Moses AM. Bone quality assessment in type 2 diabetes mellitus. Osteoporos Int 2014; 25:1969-73; PMID:24718377; http://dx.doi.org/10.1007/s00198-014-2704-7
   PubMed Web of Science ®Google Scholar
• de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005; 16:1713-20; PMID:15940395; http://dx.doi.org/10.1007/s00198-005-1909-1
   PubMed Web of Science ®Google Scholar
• Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: the Nurses’ Health Study. Diabetes Care 2006; 29:1573-8; PMID:16801581; http://dx.doi.org/10.2337/dc06-0440
   PubMed Web of Science ®Google Scholar
• Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166:495-505; PMID:17575306; http://dx.doi.org/10.1093/aje/kwm106
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180:32-9; PMID:19073651; http://dx.doi.org/10.1503/cmaj.080486
   PubMed Web of Science ®Google Scholar
• McDonough AK, Rosenthal RS, Cao X, Saag KG. The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab 2008; 4:507-13; PMID:18695700; http://dx.doi.org/10.1038/ncpendmet0920
   PubMedGoogle Scholar
• Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145:401-6; PMID:14500573; http://dx.doi.org/10.1210/en.2003-0746
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91:3349-54; PMID:16608888; http://dx.doi.org/10.1210/jc.2005-2226
   PubMed Web of Science ®Google Scholar
• Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30:1574-6; PMID:17363747; http://dx.doi.org/10.2337/dc06-2606
   PubMed Web of Science ®Google Scholar
• Oikawa A, Siragusa M, Quaini F, Mangialardi G, Katare RG, Caporali A, van Buul JD, van Alphen FP, Graiani G, Spinetti G, et al. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol 2010; 30:498-508; PMID:20042708; http://dx.doi.org/10.1161/ATVBAHA.109.200154
   PubMedGoogle Scholar
• Spinetti G, Cordella D, Fortunato O, Sangalli E, Losa S, Gotti A, Carnelli F, Rosa F, Riboldi S, Sessa F, et al. Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ Res 2013; 112:510-22; PMID:23250986; http://dx.doi.org/10.1161/CIRCRESAHA.112.300598
   PubMedGoogle Scholar
• Fadini GP, Agostini C, Avogaro A. Characterization of endothelial progenitor cells. Biochem Biophys Res Commun 2005; 336:1-2; PMID:16084490; http://dx.doi.org/10.1016/j.bbrc.2005.07.119
   PubMedGoogle Scholar
• Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004; 53:195-9; PMID:14693715; http://dx.doi.org/10.2337/diabetes.53.1.195
   PubMed Web of Science ®Google Scholar
• Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89:E1-7; PMID:11440984; http://dx.doi.org/10.1161/hh1301.093953
   PubMed Web of Science ®Google Scholar
• Yue WS, Lau KK, Siu CW, Wang M, Yan GH, Yiu KH, Tse HF. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2011; 10:113; PMID:22185563; http://dx.doi.org/10.1186/1475-2840-10-113
   PubMed Web of Science ®Google Scholar
• Keats EC, Dominguez JM 2nd, Grant MB, Khan ZA. Switch from canonical to noncanonical Wnt signaling mediates high glucose-induced adipogenesis. Stem Cells 2014; 32:1649-60; PMID:24496952; http://dx.doi.org/10.1002/stem.1659
   PubMedGoogle Scholar
• Keats E, Khan ZA. Unique responses of stem cell-derived vascular endothelial and mesenchymal cells to high levels of glucose. PLoS One 2012; 7:e38752; PMID:22701703; http://dx.doi.org/10.1371/journal.pone.0038752
   PubMed Web of Science ®Google Scholar
• Albiero M, Poncina N, Tjwa M, Ciciliot S, Menegazzo L, Ceolotto G, Vigili de Kreutzenberg S, Moura R, Giorgio M, Pelicci P, et al. Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. Diabetes 2014; 63:1353-65; PMID:24270983; http://dx.doi.org/10.2337/db13-0894
   PubMedGoogle Scholar
• Barthelmes D, Irhimeh MR, Gillies MC, Karimipour M, Zhou M, Zhu L, Shen WY. Diabetes impairs mobilization of mouse bone marrow-derived Lin(-)/VEGF-R2(+) progenitor cells. Blood Cells Mol Dis 2013; 51:163-73; PMID:23714230; http://dx.doi.org/10.1016/j.bcmd.2013.05.002
   PubMedGoogle Scholar
• Green H, Meuth M. An established pre-adipose cell line and its differentiation in culture. Cell 1974; 3:127-33; PMID:4426090; http://dx.doi.org/10.1016/0092-8674(74)90116-0
   PubMed Web of Science ®Google Scholar
• Novakofski J. Adipogenesis: usefulness of in vitro and in vivo experimental models. J Anim Sci 2004; 82:905-15; PMID:15032449
   PubMed Web of Science ®Google Scholar
• Nakamura T, Shiojima S, Hirai Y, Iwama T, Tsuruzoe N, Hirasawa A, Katsuma S, Tsujimoto G. Temporal gene expression changes during adipogenesis in human mesenchymal stem cells. Biochem Biophys Res Commun 2003; 303:306-12; PMID:12646203; http://dx.doi.org/10.1016/S0006-291X(03)00325-5
   PubMedGoogle Scholar
• Camp HS, Ren D, Leff T. Adipogenesis and fat-cell function in obesity and diabetes. Trends Mol Med 2002; 8:442-7; PMID:12223316; http://dx.doi.org/10.1016/S1471-4914(02)02396-1
   PubMed Web of Science ®Google Scholar
• Yu WH, Li FG, Chen XY, Li JT, Wu YH, Huang LH, Wang Z, Li P, Wang T, Lahn BT, et al. PPARγ suppression inhibits adipogenesis but does not promote osteogenesis of human mesenchymal stem cells. Int J Biochem Cell Biol 2012; 44:377-84; PMID:22120652; http://dx.doi.org/10.1016/j.biocel.2011.11.013
   PubMed Web of Science ®Google Scholar
• Fajas L, Auboeuf D, Raspé E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997; 272:18779-89; PMID:9228052; http://dx.doi.org/10.1074/jbc.272.30.18779
   PubMed Web of Science ®Google Scholar
• Saladin R, Fajas L, Dana S, Halvorsen YD, Auwerx J, Briggs M. Differential regulation of peroxisome proliferator activated receptor gamma1 (PPARgamma1) and PPARgamma2 messenger RNA expression in the early stages of adipogenesis. Cell Growth Differ 1999; 10:43-8; PMID:9950217
   PubMedGoogle Scholar
• Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 2000; 16:145-71; PMID:11031233; http://dx.doi.org/10.1146/annurev.cellbio.16.1.145
   PubMed Web of Science ®Google Scholar
• Brun RP, Kim JB, Hu E, Altiok S, Spiegelman BM. Adipocyte differentiation: a transcriptional regulatory cascade. Curr Opin Cell Biol 1996; 8:826-32; PMID:8939673; http://dx.doi.org/10.1016/S0955-0674(96)80084-6
   PubMedGoogle Scholar
• Garten A, Schuster S, Kiess W. The insulin-like growth factors in adipogenesis and obesity. [v-vi.]. Endocrinol Metab Clin North Am 2012; 41:283-95, v-vi; PMID:22682631; http://dx.doi.org/10.1016/j.ecl.2012.04.011
   PubMedGoogle Scholar
• Rodríguez Fernández JL, Ben-Ze’ev A. Regulation of fibronectin, integrin and cytoskeleton expression in differentiating adipocytes: inhibition by extracellular matrix and polylysine. Differentiation 1989; 42:65-74; PMID:2633939; http://dx.doi.org/10.1111/j.1432-0436.1989.tb00608.x
   PubMed Web of Science ®Google Scholar
• Bortell R, Owen TA, Ignotz R, Stein GS, Stein JL. TGF β 1 prevents the down-regulation of type I procollagen, fibronectin, and TGF β 1 gene expression associated with 3T3-L1 pre-adipocyte differentiation. J Cell Biochem 1994; 54:256-63; PMID:8175900; http://dx.doi.org/10.1002/jcb.240540214
   PubMed Web of Science ®Google Scholar
• Cawthorn WP, Heyd F, Hegyi K, Sethi JK. Tumour necrosis factor-α inhibits adipogenesis via a β-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ 2007; 14:1361-73; PMID:17464333; http://dx.doi.org/10.1038/sj.cdd.4402127
   PubMed Web of Science ®Google Scholar
• Petruschke T, Hauner H. Tumor necrosis factor-alpha prevents the differentiation of human adipocyte precursor cells and causes delipidation of newly developed fat cells. J Clin Endocrinol Metab 1993; 76:742-7; PMID:8445033
   PubMed Web of Science ®Google Scholar
• Spinella-Jaegle S, Rawadi G, Kawai S, Gallea S, Faucheu C, Mollat P, Courtois B, Bergaud B, Ramez V, Blanchet AM, et al. Sonic hedgehog increases the commitment of pluripotent mesenchymal cells into the osteoblastic lineage and abolishes adipocytic differentiation. J Cell Sci 2001; 114:2085-94; PMID:11493644
   PubMed Web of Science ®Google Scholar
• Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci 1992; 102:341-51; PMID:1400636
   PubMed Web of Science ®Google Scholar
• Song L, Liu M, Ono N, Bringhurst FR, Kronenberg HM, Guo J. Loss of wnt/β-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes. J Bone Miner Res 2012; 27:2344-58; PMID:22729939; http://dx.doi.org/10.1002/jbmr.1694
   PubMed Web of Science ®Google Scholar
• Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009; 66:236-53; PMID:18854943; http://dx.doi.org/10.1007/s00018-008-8429-z
   PubMed Web of Science ®Google Scholar
• James AW, Leucht P, Levi B, Carre AL, Xu Y, Helms JA, Longaker MT. Sonic Hedgehog influences the balance of osteogenesis and adipogenesis in mouse adipose-derived stromal cells. Tissue Eng Part A 2010; 16:2605-16; PMID:20367246; http://dx.doi.org/10.1089/ten.tea.2010.0048
   PubMedGoogle Scholar
• Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD, Macdougald OA. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein α and peroxisome proliferator-activated receptor γ. J Biol Chem 2007; 282:14515-24; PMID:17351296; http://dx.doi.org/10.1074/jbc.M700030200
   PubMed Web of Science ®Google Scholar
• Li Y-M, Schilling T, Benisch P, Zeck S, Meissner-Weigl J, Schneider D, Limbert C, Seufert J, Kassem M, Schütze N, et al. Effects of high glucose on mesenchymal stem cell proliferation and differentiation. Biochem Biophys Res Commun 2007; 363:209-15; PMID:17868648; http://dx.doi.org/10.1016/j.bbrc.2007.08.161
   PubMedGoogle Scholar
• Shilpa K, Dinesh T, Lakshmi BS. An In Vitro Model to Probe the Regulation of Adipocyte Differentiation under Hyperglycemia. Diabetes Metab J 2013; 37:176-80; PMID:23807920; http://dx.doi.org/10.4093/dmj.2013.37.3.176
   PubMedGoogle Scholar
• Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 2000; 97:11371-6; PMID:11027337; http://dx.doi.org/10.1073/pnas.97.21.11371
   PubMed Web of Science ®Google Scholar
• Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP, Rajala MW, Du X, Rollman B, Li W, et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 2005; 280:4617-26; PMID:15536073; http://dx.doi.org/10.1074/jbc.M411863200
   PubMed Web of Science ®Google Scholar
• Chuang CC, Yang RS, Tsai KS, Ho FM, Liu SH. Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt, and peroxisome proliferator-activated receptor γ signaling. Endocrinology 2007; 148:4267-75; PMID:17540722; http://dx.doi.org/10.1210/en.2007-0179
   PubMed Web of Science ®Google Scholar
• Downward J. Lipid-regulated kinases: some common themes at last. Science 1998; 279:673-4; PMID:9471728; http://dx.doi.org/10.1126/science.279.5351.673
   PubMedGoogle Scholar
• Xu J, Liao K. Protein kinase B/AKT 1 plays a pivotal role in insulin-like growth factor-1 receptor signaling induced 3T3-L1 adipocyte differentiation. J Biol Chem 2004; 279:35914-22; PMID:15192111; http://dx.doi.org/10.1074/jbc.M402297200
   PubMed Web of Science ®Google Scholar
• Cho HJ, Park J, Lee HW, Lee YS, Kim JB. Regulation of adipocyte differentiation and insulin action with rapamycin. Biochem Biophys Res Commun 2004; 321:942-8; PMID:15358118; http://dx.doi.org/10.1016/j.bbrc.2004.07.050
   PubMed Web of Science ®Google Scholar
• Guillet-Deniau I, Pichard A-L, Koné A, Esnous C, Nieruchalski M, Girard J, Prip-Buus C. Glucose induces de novo lipogenesis in rat muscle satellite cells through a sterol-regulatory-element-binding-protein-1c-dependent pathway. J Cell Sci 2004; 117:1937-44; PMID:15039461; http://dx.doi.org/10.1242/jcs.01069
   PubMedGoogle Scholar
• Yue T, Yin J, Li F, Li D, Du M. High glucose induces differentiation and adipogenesis in porcine muscle satellite cells via mTOR. BMB Rep 2010; 43:140-5; PMID:20193134; http://dx.doi.org/10.5483/BMBRep.2010.43.2.140
   PubMedGoogle Scholar
• Aguiari P, Leo S, Zavan B, Vindigni V, Rimessi A, Bianchi K, Franzin C, Cortivo R, Rossato M, Vettor R, et al. High glucose induces adipogenic differentiation of muscle-derived stem cells. Proc Natl Acad Sci U S A 2008; 105:1226-31; PMID:18212116; http://dx.doi.org/10.1073/pnas.0711402105
   PubMed Web of Science ®Google Scholar
• Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19:257-67; PMID:8742574; http://dx.doi.org/10.2337/diacare.19.3.257
   PubMed Web of Science ®Google Scholar
• Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49:1939-45; PMID:11078463; http://dx.doi.org/10.2337/diabetes.49.11.1939
   PubMed Web of Science ®Google Scholar
• Sano T, Umeda F, Hashimoto T, Nawata H, Utsumi H. Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia 1998; 41:1355-60; PMID:9833944; http://dx.doi.org/10.1007/s001250051076
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54:1615-25; PMID:15919781; http://dx.doi.org/10.2337/diabetes.54.6.1615
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404:787-90; PMID:10783895; http://dx.doi.org/10.1038/35008121
   PubMed Web of Science ®Google Scholar
• Schwartz AV. Diabetes Mellitus: Does it Affect Bone? Calcif Tissue Int 2003; 73:515-9; PMID:14517715; http://dx.doi.org/10.1007/s00223-003-0023-7
   PubMed Web of Science ®Google Scholar
• Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114:597-605; PMID:16894049; http://dx.doi.org/10.1161/CIRCULATIONAHA.106.621854
   PubMed Web of Science ®Google Scholar
• Jakuš V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004; 53:131-42; PMID:15046548
   PubMed Web of Science ®Google Scholar
• Franke S, Siggelkow H, Wolf G, Hein G. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 2007; 113:154-61; PMID:17922311; http://dx.doi.org/10.1080/13813450701602523
   PubMedGoogle Scholar
• Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 1996; 11:931-7; PMID:8797113; http://dx.doi.org/10.1002/jbmr.5650110709
   PubMed Web of Science ®Google Scholar
• Santana RB, Xu L, Chase HB, Amar S, Graves DT, Trackman PC. A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes 2003; 52:1502-10; PMID:12765963; http://dx.doi.org/10.2337/diabetes.52.6.1502
   PubMed Web of Science ®Google Scholar
• Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L, Graves DT. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007; 40:345-53; PMID:17064973; http://dx.doi.org/10.1016/j.bone.2006.09.011
   PubMed Web of Science ®Google Scholar
• Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M, Nagata K. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005; 20:1647-58; PMID:16059636; http://dx.doi.org/10.1359/JBMR.050514
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang JH. Activation of the PI3K/Akt pathway by oxidative stress mediates high glucose-induced increase of adipogenic differentiation in primary rat osteoblasts. J Cell Biochem 2013; 114:2595-602; PMID:23757055; http://dx.doi.org/10.1002/jcb.24607
   PubMed Web of Science ®Google Scholar
• Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A. Adipogenesis and WNT signalling. Trends Endocrinol Metab 2009; 20:16-24; PMID:19008118; http://dx.doi.org/10.1016/j.tem.2008.09.002
   PubMed Web of Science ®Google Scholar
• Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997; 11:3286-305; PMID:9407023; http://dx.doi.org/10.1101/gad.11.24.3286
   PubMed Web of Science ®Google Scholar
• Miller JR. The Wnts. Genome Biol 2002; 3:S3001; PMID:11806834
   PubMedGoogle Scholar
• Farmer SR. Transcriptional control of adipocyte formation. Cell Metab 2006; 4:263-73; PMID:17011499; http://dx.doi.org/10.1016/j.cmet.2006.07.001
   PubMed Web of Science ®Google Scholar
• Moldes M, Zuo Y, Morrison RF, Silva D, Park BH, Liu J, Farmer SR. Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis. Biochem J 2003; 376:607-13; PMID:12954078; http://dx.doi.org/10.1042/BJ20030426
   PubMed Web of Science ®Google Scholar
• Liu J, Farmer SR. Regulating the balance between peroxisome proliferator-activated receptor γ and β-catenin signaling during adipogenesis. A glycogen synthase kinase 3β phosphorylation-defective mutant of β-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 2004; 279:45020-7; PMID:15308623; http://dx.doi.org/10.1074/jbc.M407050200
   PubMed Web of Science ®Google Scholar
• Liu J, Wang H, Zuo Y, Farmer SR. Functional interaction between peroxisome proliferator-activated receptor γ and β-catenin. Mol Cell Biol 2006; 26:5827-37; PMID:16847334; http://dx.doi.org/10.1128/MCB.00441-06
   PubMed Web of Science ®Google Scholar
• Farmer SR. Regulation of PPARgamma activity during adipogenesis. Int J Obes (Lond) 2005; 29(Suppl 1):S13-6; PMID:15711576; http://dx.doi.org/10.1038/sj.ijo.0802907
   PubMed Web of Science ®Google Scholar
• Semënov MV, Habas R, MacDonald BT, He X. SnapShot: noncanonical Wnt signaling pathways. Cell 2007; 131: 1378. e1-. e2.
   Web of Science ®Google Scholar
• Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, Igarashi M, Youn MY, Takeyama K, Nakamura T, Mezaki Y, et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 2007; 9:1273-85; PMID:17952062; http://dx.doi.org/10.1038/ncb1647
   PubMed Web of Science ®Google Scholar
• Fleming I, MacKenzie SJ, Vernon RG, Anderson NG, Houslay MD, Kilgour E. Protein kinase C isoforms play differential roles in the regulation of adipocyte differentiation. Biochem J 1998; 333:719-27; PMID:9677333
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang D, Li F, Shi J, Song J. Different roles of protein kinase C-betaI and -delta in the regulation of adipocyte differentiation. Int J Biochem Cell Biol 2006; 38:2151-63; PMID:16950644; http://dx.doi.org/10.1016/j.biocel.2006.06.009
   PubMed Web of Science ®Google Scholar
• Frevert EU, Kahn BB. Protein kinase C isoforms epsilon, eta, delta and zeta in murine adipocytes: expression, subcellular localization and tissue-specific regulation in insulin-resistant states. Biochem J 1996; 316:865-71; PMID:8670164
   PubMed Web of Science ®Google Scholar
• Webb PR, Doyle C, Anderson NG. Protein kinase C-epsilon promotes adipogenic commitment and is essential for terminal differentiation of 3T3-F442A preadipocytes. Cell Mol Life Sci 2003; 60:1504-12; PMID:12943236; http://dx.doi.org/10.1007/s00018-003-2337-z
   PubMed Web of Science ®Google Scholar
• Accili D, Taylor SI. Targeted inactivation of the insulin receptor gene in mouse 3T3-L1 fibroblasts via homologous recombination. Proc Natl Acad Sci U S A 1991; 88:4708-12; PMID:2052553; http://dx.doi.org/10.1073/pnas.88.11.4708
   PubMed Web of Science ®Google Scholar
• Cinti S, Eberbach S, Castellucci M, Accili D. Lack of insulin receptors affects the formation of white adipose tissue in mice. A morphometric and ultrastructural analysis. Diabetologia 1998; 41:171-7; PMID:9498650; http://dx.doi.org/10.1007/s001250050886
   PubMedGoogle Scholar
• Irwin R, Lin HV, Motyl KJ, McCabe LR. Normal bone density obtained in the absence of insulin receptor expression in bone. Endocrinology 2006; 147:5760-7; PMID:16973725; http://dx.doi.org/10.1210/en.2006-0700
   PubMedGoogle Scholar
• Haffner SM, Stern MP, Hazuda HP, Pugh JA, Patterson JK. Hyperinsulinemia in a population at high risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1986; 315:220-4; PMID:3523246; http://dx.doi.org/10.1056/NEJM198607243150403
   PubMed Web of Science ®Google Scholar
• Li C, Ford ES, Zhao G, Mokdad AH. Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among U.S. adolescents: National Health and Nutrition Examination Survey 2005-2006. Diabetes Care 2009; 32:342-7; PMID:18957533; http://dx.doi.org/10.2337/dc08-1128
   PubMed Web of Science ®Google Scholar
• Zhang HH, Huang J, Düvel K, Boback B, Wu S, Squillace RM, Wu CL, Manning BD. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One 2009; 4:e6189; PMID:19593385; http://dx.doi.org/10.1371/journal.pone.0006189
   PubMed Web of Science ®Google Scholar
• McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 2007; 102:1343-57; PMID:17975793; http://dx.doi.org/10.1002/jcb.21573
   PubMed Web of Science ®Google Scholar
• Kershnar AK, Daniels SR, Imperatore G, Palla SL, Petitti DB, Pettitt DJ, Marcovina S, Dolan LM, Hamman RF, Liese AD, et al. Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr 2006; 149:314-9; PMID:16939739; http://dx.doi.org/10.1016/j.jpeds.2006.04.065
   PubMed Web of Science ®Google Scholar
• O’Brien T, Nguyen TT, Zimmerman BR. Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 1998; 73:969-76; PMID:9787748; http://dx.doi.org/10.4065/73.10.969
   PubMed Web of Science ®Google Scholar
• Christeff N, Homo-Delarche F, Thobie N, Durant S, Dardenne M, Nunez EA. Free fatty acid profiles in the non-obese diabetic (NOD) mouse: basal serum levels and effects of endocrine manipulation. Prostaglandins Leukot Essent Fatty Acids 1994; 51:125-31; PMID:7972266; http://dx.doi.org/10.1016/0952-3278(94)90088-4
   PubMedGoogle Scholar
• Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 1992; 6:1634-41; PMID:1333051
   PubMed Web of Science ®Google Scholar
• Bragt MCE, Popeijus HE. Peroxisome proliferator-activated receptors and the metabolic syndrome. Physiol Behav 2008; 94:187-97; PMID:18191967; http://dx.doi.org/10.1016/j.physbeh.2007.11.053
   PubMedGoogle Scholar
• Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-γ 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002; 143:2376-84; PMID:12021203
   PubMed Web of Science ®Google Scholar
• Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014; 510:542-6; PMID:24847880; http://dx.doi.org/10.1038/nature13270
   PubMed Web of Science ®Google Scholar
• Molinuevo MS, Schurman L, McCarthy AD, Cortizo AM, Tolosa MJ, Gangoiti MV, Arnol V, Sedlinsky C. Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res 2010; 25:211-21; PMID:19594306; http://dx.doi.org/10.1359/jbmr.090732
   PubMed Web of Science ®Google Scholar
• Grossman SL, Lessem J. Mechanisms and clinical effects of thiazolidinediones. Expert Opin Investig Drugs 1997; 6:1025-40; PMID:15989661; http://dx.doi.org/10.1517/13543784.6.8.1025
   PubMedGoogle Scholar
• Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62:1805-37; PMID:12149047; http://dx.doi.org/10.2165/00003495-200262120-00007
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 2005; 366:1241-2; PMID:16214581; http://dx.doi.org/10.1016/S0140-6736(05)67504-6
   PubMed Web of Science ®Google Scholar
• Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 2010; 12:716-21; PMID:20590749; http://dx.doi.org/10.1111/j.1463-1326.2010.01225.x
   PubMed Web of Science ®Google Scholar
• Bodmer M, Meier C, Kraenzlin ME, Meier CR. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 2009; 32:539-47; PMID:19530741; http://dx.doi.org/10.2165/00002018-200932070-00001
   PubMed Web of Science ®Google Scholar
• Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, et al.; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31:845-51; PMID:18223031; http://dx.doi.org/10.2337/dc07-2270
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 2010; 8:178-84; PMID:20809203; http://dx.doi.org/10.1007/s11914-010-0027-y
   PubMedGoogle Scholar
• Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402:880-3; PMID:10622252
   PubMed Web of Science ®Google Scholar
• Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106:473-81; PMID:10953022; http://dx.doi.org/10.1172/JCI10842
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Cellai I, Luciani P, Deledda C, Baglioni S, Giuliani C, Saccardi R, Mazzanti B, Dal Pozzo S, Mannucci E, et al. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 2007; 30:RC26-30; PMID:17993761; http://dx.doi.org/10.1007/BF03350807
   PubMed Web of Science ®Google Scholar
• Hallakou S, Doaré L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, Ferré P. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46:1393-9; PMID:9287037; http://dx.doi.org/10.2337/diabetes.46.9.1393
   PubMed Web of Science ®Google Scholar
• Khan MA, St Peter JV, Xue JLA. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25:708-11; PMID:11919129; http://dx.doi.org/10.2337/diacare.25.4.708
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87:2784-91; PMID:12050251; http://dx.doi.org/10.1210/jcem.87.6.8567
   PubMed Web of Science ®Google Scholar
• Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22:908-12; PMID:10372240; http://dx.doi.org/10.2337/diacare.22.6.908
   PubMed Web of Science ®Google Scholar
• Beck GR Jr., Khazai NB, Bouloux GF, Camalier CE, Lin Y, Garneys LM, Siqueira J, Peng L, Pasquel F, Umpierrez D, et al. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Transl Res 2013; 161:145-55; PMID:23022285; http://dx.doi.org/10.1016/j.trsl.2012.08.006
   PubMed Web of Science ®Google Scholar
• Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999; 140:5060-5; PMID:10537132
   PubMed Web of Science ®Google Scholar
• Bruedigam C, Eijken M, Koedam M, van de Peppel J, Drabek K, Chiba H, van Leeuwen JP. A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone. Stem Cells 2010; 28:916-27; PMID:20213769
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999; 74:357-71; PMID:10412038; http://dx.doi.org/10.1002/(SICI)1097-4644(19990901)74: 3≤357::AID-JCB5≥3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• Jeon MJ, Kim JA, Kwon SH, Kim SW, Park KS, Park SW, Kim SY, Shin CS. Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem 2003; 278:23270-7; PMID:12704187; http://dx.doi.org/10.1074/jbc.M211610200
   PubMed Web of Science ®Google Scholar
• Khan E, Abu-Amer Y. Activation of peroxisome proliferator-activated receptor-γ inhibits differentiation of preosteoblasts. J Lab Clin Med 2003; 142:29-34; PMID:12878983; http://dx.doi.org/10.1016/S0022-2143(03)00058-1
   PubMed Web of Science ®Google Scholar
• Okazaki R, Miura M, Toriumi M, Taguchi M, Hirota Y, Fukumoto S, Fujita T, Tanaka K, Takeuchi A. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 1999; 46:795-801; PMID:10724355; http://dx.doi.org/10.1507/endocrj.46.795
   PubMed Web of Science ®Google Scholar
• Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 2003; 21:166-71; PMID:12720051; http://dx.doi.org/10.1007/s007740300026
   PubMed Web of Science ®Google Scholar
• Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil Tutuncu N, Guvener Demirag N. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007; 92:3523-30; PMID:17595249; http://dx.doi.org/10.1210/jc.2007-0431
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008; 93:1696-701; PMID:18285411; http://dx.doi.org/10.1210/jc.2007-2249
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92:1305-10; PMID:17264176; http://dx.doi.org/10.1210/jc.2006-2646
   PubMed Web of Science ®Google Scholar
• Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004; 113:846-55; PMID:15067317; http://dx.doi.org/10.1172/JCI200419900
   PubMed Web of Science ®Google Scholar
• Kawaguchi H, Akune T, Yamaguchi M, Ohba S, Ogata N, Chung UI, Kubota N, Terauchi Y, Kadowaki T, Nakamura K. Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab 2005; 23:275-9; PMID:15981022; http://dx.doi.org/10.1007/s00774-005-0599-2
   PubMedGoogle Scholar
• Song L, Liu M, Ono N, Bringhurst FR, Kronenberg HM, Guo J. Loss of wnt/β-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes. J Bone Miner Res 2012; 27:2344-58; PMID:22729939; http://dx.doi.org/10.1002/jbmr.1694
   PubMed Web of Science ®Google Scholar
• Botolin S, McCabe LR. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol 2006; 209:967-76; PMID:16972249; http://dx.doi.org/10.1002/jcp.20804
   PubMedGoogle Scholar
• Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 2006; 99:411-24; PMID:16619259; http://dx.doi.org/10.1002/jcb.20842
   PubMed Web of Science ®Google Scholar
• He H, Liu R, Desta T, Leone C, Gerstenfeld LC, Graves DT. Diabetes causes decreased osteoclastogenesis, reduced bone formation, and enhanced apoptosis of osteoblastic cells in bacteria stimulated bone loss. Endocrinology 2004; 145:447-52; PMID:14525917; http://dx.doi.org/10.1210/en.2003-1239
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang X, Zheng J, Yang J. High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG-63 cells through cAMP/protein kinase A/extracellular signal-regulated kinase pathway. Mol Cell Biochem 2010; 338:115-22; PMID:19949837; http://dx.doi.org/10.1007/s11010-009-0344-6
   PubMed Web of Science ®Google Scholar
• Zayzafoon M, Stell C, Irwin R, McCabe LR. Extracellular glucose influences osteoblast differentiation and c-Jun expression. J Cell Biochem 2000; 79:301-10; PMID:10967557; http://dx.doi.org/10.1002/1097-4644(20001101)79: 2≤301::AID-JCB130≥3.0.CO;2-0
   PubMedGoogle Scholar
• Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941-6; PMID:11479627; http://dx.doi.org/10.1038/90984
   PubMed Web of Science ®Google Scholar
• Yokota T, Meka CS, Medina KL, Igarashi H, Comp PC, Takahashi M, Nishida M, Oritani K, Miyagawa J, Funahashi T, et al. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest 2002; 109:1303-10; PMID:12021245; http://dx.doi.org/10.1172/JCI0214506
   PubMed Web of Science ®Google Scholar
• Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, Yoshikawa H, Shimomura I. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005; 331:520-6; PMID:15850790; http://dx.doi.org/10.1016/j.bbrc.2005.03.210
   PubMed Web of Science ®Google Scholar
• Lee HW, Kim SY, Kim AY, Lee EJ, Choi J-Y, Kim JB. Adiponectin stimulates osteoblast differentiation through induction of COX2 in mesenchymal progenitor cells. Stem Cells 2009; 27:2254-62; PMID:19522015; http://dx.doi.org/10.1002/stem.144
   PubMedGoogle Scholar
• Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol 2007; 8:51; PMID:18047638; http://dx.doi.org/10.1186/1471-2121-8-51
   PubMedGoogle Scholar
• Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1:1155-61; PMID:7584987; http://dx.doi.org/10.1038/nm1195-1155
   PubMed Web of Science ®Google Scholar
• Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334:292-5; PMID:8532024; http://dx.doi.org/10.1056/NEJM199602013340503
   PubMed Web of Science ®Google Scholar
• Kiess W, Anil M, Blum WF, Englaro P, Juul A, Attanasio A, Dötsch J, Rascher W. Serum leptin levels in children and adolescents with insulin-dependent diabetes mellitus in relation to metabolic control and body mass index. Eur J Endocrinol 1998; 138:501-9; PMID:9625360; http://dx.doi.org/10.1530/eje.0.1380501
   PubMed Web of Science ®Google Scholar
• Cirmanová V, Bayer M, Stárka L, Zajícková K. The effect of leptin on bone: an evolving concept of action. Physiol Res 2008; 57(Suppl 1):S143-51; PMID:18271682
   PubMedGoogle Scholar
• Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000; 92:73-8; PMID:11024568; http://dx.doi.org/10.1016/S0167-0115(00)00152-X
   PubMed Web of Science ®Google Scholar
• Martin A, David V, Malaval L, Lafage-Proust M-H, Vico L, Thomas T. Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-I pathway. Endocrinology 2007; 148:3419-25; PMID:17431002; http://dx.doi.org/10.1210/en.2006-1541
   PubMed Web of Science ®Google Scholar
• Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111:305-17; PMID:12419242; http://dx.doi.org/10.1016/S0092-8674(02)01049-8
   PubMed Web of Science ®Google Scholar
• Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin Inhibits Bone Formation through a Hypothalamic Relay: A Central Control of Bone Mass. Cell 2000; 100:197-207.
   PubMed Web of Science ®Google Scholar
• Motyl KJ, McCabe LR. Leptin treatment prevents type I diabetic marrow adiposity but not bone loss in mice. J Cell Physiol 2009; 218:376-84; PMID:18932203; http://dx.doi.org/10.1002/jcp.21608
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95:2409-15; PMID:7738205; http://dx.doi.org/10.1172/JCI117936
   PubMed Web of Science ®Google Scholar
• Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, Schwarz EM, O’Keefe RJ, Xing L. TNF-alpha and pathologic bone resorption. Keio J Med 2005; 54:127-31; PMID:16237274; http://dx.doi.org/10.2302/kjm.54.127
   PubMedGoogle Scholar
• Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000; 275:4858-64; PMID:10671521; http://dx.doi.org/10.1074/jbc.275.7.4858
   PubMed Web of Science ®Google Scholar